- Home
- CURV vs DSGN Comparison
CURV vs DSGN Comparison
Compare CURV & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- DSGN
- Stock Information
- Founded
- CURV 2001
- DSGN 2017
- Country
- CURV United States
- DSGN United States
- Employees
- CURV N/A
- DSGN N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CURV Consumer Discretionary
- DSGN Health Care
- Exchange
- CURV Nasdaq
- DSGN Nasdaq
- Market Cap
- CURV 248.6M
- DSGN 208.9M
- IPO Year
- CURV 2021
- DSGN 2021
- Fundamental
- Price
- CURV $2.28
- DSGN $5.26
- Analyst Decision
- CURV Hold
- DSGN
- Analyst Count
- CURV 4
- DSGN 0
- Target Price
- CURV $5.00
- DSGN N/A
- AVG Volume (30 Days)
- CURV 551.3K
- DSGN 141.5K
- Earning Date
- CURV 09-04-2025
- DSGN 08-07-2025
- Dividend Yield
- CURV N/A
- DSGN N/A
- EPS Growth
- CURV N/A
- DSGN N/A
- EPS
- CURV 0.09
- DSGN N/A
- Revenue
- CURV $1,089,931,000.00
- DSGN N/A
- Revenue This Year
- CURV N/A
- DSGN N/A
- Revenue Next Year
- CURV N/A
- DSGN N/A
- P/E Ratio
- CURV $25.19
- DSGN N/A
- Revenue Growth
- CURV N/A
- DSGN N/A
- 52 Week Low
- CURV $2.08
- DSGN $2.60
- 52 Week High
- CURV $7.25
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CURV 35.57
- DSGN 61.90
- Support Level
- CURV $2.16
- DSGN $4.68
- Resistance Level
- CURV $2.35
- DSGN $5.60
- Average True Range (ATR)
- CURV 0.14
- DSGN 0.39
- MACD
- CURV 0.06
- DSGN 0.04
- Stochastic Oscillator
- CURV 36.79
- DSGN 79.95
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.